Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin, +14

Investigational New Drugs

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey, +19

Cell Reports

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel, +7

Drug Metabolism and Disposition

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster, +27

Cancer Cell

Cdk6 Inhibitor AbemaciclibSignal TransductionSignaling PathwayGenomic AberrationsCell Regulation +8

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, +11

Oncotarget

Total Synthesis of (+)-Aspidospermidine:  A New Strategy for the Enantiospecific Synthesis of Aspidosperma Alkaloids

Joseph P. Marino, M. Belén Rubio, Ganfeng Cao, +1

Journal of the American Chemical Society

BiosynthesisBioorganic ChemistryAspidosperma AlkaloidsBiochemistryEngineering +12

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

Sonya C. Tate, Shufen Cai, Rose T. Ajamie, +7

Clinical Cancer Research

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, +18

Molecular Cancer Therapeutics

Drug TargetAntitumor ActivityP38 MapkPharmacotherapyCancer Biology +18

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties

Mary M. Mader, Alfonso de Dios, Chuan Shih, +27

Bioorganic & Medicinal Chemistry Letters

Molecular PharmacologyMedicinal ChemistryBiochemistryMedicineNatural Sciences +6

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau, +23

Molecular Cancer Therapeutics

Tumor BiologyMedicineMalignant Blood DisorderImmunologyCell Death +12